EP
VERA icon

Eversept Partners’s Vera Therapeutics VERA Stock Holding History

Eversept Partners’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.4M Sell
2,173,286
-899,018
-29% -$38.7M 4.61% 5
2025
Q4 		$156M Buy
3,072,304
+264,468
+9% +$9.39M 7.84% 1
2025
Q3 		$81.6M Buy
2,807,836
+424,781
+18% +$9.82M 5.62% 5
2025
Q2 		$56.1M Buy
2,383,055
+484,251
+26% +$10.9M 5.16% 4
2025
Q1 		$45.6M Buy
1,898,804
+298,789
+19% +$9.6M 4.63% 6
2024
Q4 		$67.7M Sell
1,600,015
-450,142
-22% -$19.9M 6.01% 4
2024
Q3 		$90.6M Buy
2,050,157
+6,943
+0.3% +$263K 6.21% 4
2024
Q2 		$73.9M Buy
2,043,214
+219,433
+12% +$8.7M 5.06% 8
2024
Q1 		$78.6M Sell
1,823,781
-91,049
-5% -$3.24M 5.25% 6
2023
Q4 		$29.5M Buy
1,914,830
+436,341
+30% +$5.54M 2.59% 14
2023
Q3 		$20.3M Sell
1,478,489
-262,462
-15% -$4.5M 1.72% 16
2023
Q2 		$27.9M Sell
1,740,951
-47,578
-3% -$430K 2.34% 11
2023
Q1 		$13.9M Buy
1,788,529
+1,377,221
+335% +$10.6M 0.97% 23
2022
Q4 		$7.96M Buy
411,308
+255,179
+163% +$4.62M 0.7% 33
2022
Q3 		$3.33M Buy
+156,129
New +$2.92M 0.29% 43

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eversept Partners's VERA Position: Q1 2026 in Review

Eversept Partners reduced its Vera Therapeutics (VERA) stake by 29% in Q1 2026, selling an estimated $38.7M and leaving 2,173,286 shares worth $87.4M. The position accounts for 4.61% of the portfolio, ranked #5.

Eversept Partners first reported a position in VERA in Q3 2022 and has held it in 15 quarters since. The position peaked at $156M in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Eversept Partners held 2,173,286 shares of Vera Therapeutics worth $87.4M as of Q1 2026.
  • Eversept Partners sold 899,018 Vera Therapeutics shares in Q1 2026, an estimated $38.7M.
  • Vera Therapeutics made up 4.61% of Eversept Partners's portfolio in Q1 2026, its #5 holding.
  • Eversept Partners first reported a position in Vera Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Eversept Partners's Vera Therapeutics position peaked at $156M in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.